Leap Therapeutics LPTX Stock
Leap Therapeutics Price Chart
Leap Therapeutics LPTX Financial and Trading Overview
| Leap Therapeutics stock price | 3.21 USD |
| Previous Close | 0.65 USD |
| Open | 0.65 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 800 |
| Day's Range | 0.61 - 0.67 USD |
| 52 Week Range | 0.27 - 1.86 USD |
| Volume | 838.49K USD |
| Avg. Volume | 1M USD |
| Market Cap | 72.24M USD |
| Beta (5Y Monthly) | 0.675 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.98 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.5 USD |
LPTX Valuation Measures
| Enterprise Value | 38.54M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.8333334 |
| PEG Ratio (5 yr expected) | 0.53 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.5527427 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.445 |
Trading Information
Leap Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.675 |
| 52-Week Change | -40.099% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.86 USD |
| 52 Week Low | 0.27 USD |
| 50-Day Moving Average | 0.53 USD |
| 200-Day Moving Average | 0.65 USD |
LPTX Share Statistics
| Avg. Volume (3 month) | 1M USD |
| Avg. Daily Volume (10-Days) | 1M USD |
| Shares Outstanding | 119.41M |
| Float | 81.97M |
| Short Ratio | 8.13 |
| % Held by Insiders | 8.27% |
| % Held by Institutions | 33.59% |
| Shares Short | 10.23M |
| Short % of Float | 9.13% |
| Short % of Shares Outstanding | 8.57% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -50.93% |
| Return on Equity (ttm) | -88.47% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -86555000 USD |
| Net Income Avi to Common (ttm) | -86083000 USD |
| Diluted EPS (ttm) | -0.67 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 102.04M USD |
| Total Cash Per Share (mrq) | 0.86 USD |
| Total Debt (mrq) | 617K USD |
| Total Debt/Equity (mrq) | 0.64 USD |
| Current Ratio (mrq) | 10.154 |
| Book Value Per Share (mrq) | 0.237 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -50226000 USD |
| Levered Free Cash Flow (ttm) | -47906500 USD |
Profile of Leap Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 47 Thorndike Street |
| ZIP | 02141 |
| Phone | 617 714 0360 |
| Website | https://www.leaptx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 44 |
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Q&A For Leap Therapeutics Stock
What is a current LPTX stock price?
Leap Therapeutics LPTX stock price today per share is 3.21 USD.
How to purchase Leap Therapeutics stock?
You can buy LPTX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Leap Therapeutics?
The stock symbol or ticker of Leap Therapeutics is LPTX.
Which industry does the Leap Therapeutics company belong to?
The Leap Therapeutics industry is Biotechnology.
How many shares does Leap Therapeutics have in circulation?
The max supply of Leap Therapeutics shares is 25.84M.
What is Leap Therapeutics Price to Earnings Ratio (PE Ratio)?
Leap Therapeutics PE Ratio is now.
What was Leap Therapeutics earnings per share over the trailing 12 months (TTM)?
Leap Therapeutics EPS is -3.98 USD over the trailing 12 months.
Which sector does the Leap Therapeutics company belong to?
The Leap Therapeutics sector is Healthcare.
Leap Therapeutics LPTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}